---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134805"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:19:37.292466+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports Q1 net loss $16.9M; cash $566.5M; cretostimogene 75.2% CR rate in BCG-unresponsive NMIBC

## Summary
- Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).
- Cash and securities $566.5M as of Mar 31, 2024, compared to $187.7M at Dec 31, 2023; runway sufficient through 2027.
- Cretostimogene monotherapy achieved 75.2% complete response (79/105) in BOND-003 Phase 3 trial in BCG-unresponsive HR-NMIBC.
- Completed oversubscribed $437M IPO in 2024; first Pt dosed in PIVOT-006 Phase 3; CORE-001 combo data to be presented at ASCO June 2024.

## SEC filing metadata
- accession: 0001193125-24-134805
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/0001193125-24-134805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/d774503d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134805
- JSON: https://secwatch.observer/filing/0001193125-24-134805.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134805.txt

## Key facts
- Earnings Releases
  CG Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income $16.9 million, or ($0.36) per share, EPS ($0.36) per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: $16.9 million, or ($0.36) per share
  - EPS: ($0.36) per share
  - Result: reported results
  source text: CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/0001193125-24-134805-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.